Scientific deep-dive
GLP-1 Drugs in Teenagers: What 18 Trials Show
Eighteen randomized trials in 1,402 children and adolescents with obesity, prediabetes or type 2 diabetes found improvements across every metabolic measure. Weight fell 3.02 kg more than on placebo, and the median treatment duration across all of them was half a year.
The evidence for GLP-1 drugs in children and adolescents now runs to 18 randomized trials and 1,402 participants with obesity, prediabetes or type 2 diabetes, and the results are consistently positive across every metabolic measure.[1] Two numbers deserve to sit beside them: mean weight loss was 3.02 kg more than on placebo, and the median treatment duration across all those trials was half a year.
What the trials found
| Outcome | Change against placebo |
|---|---|
| Body weight | −3.02 kg (95% CI −4.98 to −1.06) |
| BMI | −1.45 (95% CI −2.40 to −0.49) |
| BMI standard deviation score | −0.20 (95% CI −0.36 to −0.05) |
| BMI percentile | −7.24% (95% CI −12.97 to −1.51) |
| HbA1c | −0.44% (95% CI −0.68 to −0.21) |
| Fasting glucose | −9.92 mg/dL (95% CI −16.20 to −3.64) |
| Systolic blood pressure | −2.73 mm Hg (95% CI −4.04 to −1.43) |
Every one of those is a real improvement with a confidence interval clear of zero. Gastrointestinal adverse events increased, which is expected. And on suicidal ideation or behaviors, the outcome that frightens parents most, there was no significant difference.[1]
The weight number is much smaller than adults see
Three kilos is not what most people expect from a class of drugs discussed in terms of losing a fifth of your body weight. The gap has several explanations. The pooled trials include older and weaker drugs alongside newer ones, follow-up is short, and a growing child’s weight is not a fixed target the way an adult’s is. That last point is why BMI percentile and BMI standard deviation score are the more meaningful rows.
Against placebo, the pooled weight difference was about three kilos, for a class of drugs discussed in terms of losing a fifth of body weight.
That does not make the result unimportant. A 7.24% drop in BMI percentile and a blood pressure reduction in a thirteen-year-old are meaningful over a lifetime, as is anything that lowers the insulin resistance behind signs such as acanthosis nigricans. It does mean that expectations set by adult coverage do not apply.
Six months is the whole evidence base
The median treatment duration across these trials was 0.51 years, with an interquartile range of three months to one year.[1] This matters more here than in almost any other population.
- A child starting at 13 could be on treatment for decades. Six months of evidence is a thin basis for that.
- Puberty is a developmental window, and effects on growth, bone accrual and pubertal timing need years to observe, not months.
- The reassuring psychiatric finding carries the same limit. The authors say directly that the data covered a relatively short follow-up.
- Nothing here speaks to what happens on stopping, which in adults means most of the weight returning. In a growing child that question has no adult analog at all.
A separate analysis of STEP TEENS reports what happened to insulin resistance, liver enzymes and lipids in that trial’s participants (see what changed in the teenagers’ bloodwork). Those results are encouraging, but every one of them is a surrogate marker.
What a parent should ask
- Which drug, and is it approved for this age? Approval in adolescents is drug-specific and narrower than adult approval. In type 2 diabetes, tirzepatide has been tested in children aged 10 to 17.
- What is being measured? BMI percentile and standard deviation score describe a growing child; kilograms do not.
- What is the plan for stopping, or not stopping? Ask it at the start rather than at year three.
- Who is monitoring growth and puberty? This belongs with a pediatric specialist, not a telehealth intake (see what makes a prescription legitimate).
- What happens to eating behavior? Our eating disorders article covers screening, which matters more in adolescence than at any other age.
Frequently Asked Questions
References
- 1.Kotecha P, Huang W, Yeh YY, et al. Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis JAMA Pediatrics. 2025. PMID: 40952752.
Compare the sellers
Related research
The Old Cheap Drug Keeps Winning
A network meta-analysis of 41 pediatric trials found semaglutide producing the largest BMI reduction, and concluded an older, cheaper combination may be the better option.
7 min read
What Changed in the Teenagers' Bloodwork
A STEP TEENS analysis found insulin resistance down 35%, liver enzymes down 18%, and lipids improved in 12-to-17-year-olds. All of it is bloodwork, and the outcomes it stands in for are decades away.
7 min read
Tirzepatide in Ten- to Seventeen-Year-Olds
Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.
6 min read
Phentermine and a GLP-1 Together: What the Labels and Trials Show
Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.
10 min read
GLP-1 Drugs After Menopause: The Group Taking Them Most, Studied Least
One review exists on GLP-1 drugs in peri- and postmenopausal women, and it opens by describing a paucity of data. This sets out what has to be borrowed from other populations, and which borrowings hold up.
8 min read
The Cochrane Verdict, and Who Funded the Evidence
Two WHO-funded Cochrane reviews find weight loss likely to be sustained; the semaglutide review calls it clinically relevant. Both also note the trials were paid for by the manufacturers: all of them, in tirzepatide's case.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →